SCNLF (Scancell Holdings) Revenue: $6.19 Mil (TTM As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
16 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Revenue?

Scancell Holdings SCNLF 16 Revenue is $6.19 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Scancell Holdings's revenue for the six months ended in Oct. 2025 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Oct. 2025 was $6.19 Mil. Scancell Holdings's Revenue per Share for the six months ended in Oct. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2025 was $0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Scancell Holdings  (OTCPK:SCNLF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Scancell Holdings Revenue Related Terms


Scancell Holdings Revenue Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Revenue Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 6.56 0.00 6.19

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 6.19 0.00

SCNLF vs VRTX, REGN, ALNY: Revenue Comparison

For the Biotechnology subindustry, Scancell Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Revenue distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Revenue falls into.


SCNLF
16GF Score
Scancell Holdings PLC SCNLF
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Oct. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $6.19 Mil mean?
Scancell Holdings (SCNLF) has a Revenue of $6.19 Mil as of Oct. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' Revenue too high?
Scancell Holdings' current Revenue is $6.19 Mil. Overall, Scancell Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Revenue compare to VRTX and REGN?
Scancell Holdings' Revenue of $6.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Revenue is $6.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Revenue of $6.19 Mil. The current Revenue is $6.19 Mil. Scancell Holdings' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Revenue is $6.19 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
16GF Score

Get the complete analysis for SCNLF

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price